The synergy observed between ADAM17 and PI3K/AKT pathway inhibitors may work through independent inhibition of multiple cancer hallmarks, or via a more direct mechanism whereby inhibition of ADAM17 driven proteolysis and shedding of RTKs20 stabilizes and increases signaling through PI3K/AKT41,42. Here, PIK3CB is linked to cancer.